# A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

> **NCT03726879** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 454 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Placebo
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab Emtansine

## Key facts

- **NCT ID:** NCT03726879
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-11
- **Primary completion:** 2021-02-05
- **Final completion:** 2023-08-24
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2024-11-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03726879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03726879, "A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03726879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*